久保田 馨 くぼた かおる 先生

来歴等

略歴

1976年 福岡県立修猷館高等学校 卒業
1977年 熊本大学 医学部 入学
1983年 熊本大学 医学部 卒業
1983年 熊本大学医学部附属病院第２内科 内科研修
1984年 熊本中央病院 内科研修医（呼吸器・循環器）
1984年 公立玉名中央病院 内科勤務
1985年 熊本大学医学部付属病院 第２内科医員
1986年 国立療養所近畿中央病院 内科
1993年 国立がんセンター東病院 呼吸器科
1995年 Vanderbilt University Medical Center, Division of Medical Oncology 留学
1997年 国立がんセンター中央病院 内科
1999年 国立がんセンター東病院 呼吸器科
2000年 国立がんセンター東病院 病棟部病棟医長、 医療安全推進担当者、図書委員会委 員長、クリティカル・パス・ワーキンググループリーダー(2008 年 3 月まで)、 治験管理室長、医局長
2009年 国立がんセンター中央病院 総合病棟部 14A 病棟医長
2010年 国立がん研究センター中央病院 呼吸器腫瘍科外来医長
2011年 日本医科大学付属病院 化学療法科部長 日本医科大学付属病院 呼吸器内科 准教授
2012年 日本医科大学付属病院 教授 がん診療センター部長
2015年 日本医科大学付属病院 呼吸器内科 部長
2016年 日本医科大学内科学（呼吸器内科学）、 大学院医学研究科呼吸器内科学 教授
2017年 日本医科大学付属病院 化学療法科部長

論文

• Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

  Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV

• Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.

  Kaoru Kubota, Hideo Kunitoh, Takashi Seto, Naoki Shimada, Masahiro Tsuboi, Tatsuo Ohhira, Hiroaki Okamoto, Noriyuki Masuda, Riichiroh Maruyama, Masahiko Shibuya, Koshiro Watanabe

• A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.

  Pere Gascón, Rajnish Nagarkar, Martin Šmakal, Konstantinos N Syrigos, Carlos H Barrios, Jesús Cárdenas Sánchez, Li Zhang, David H Henry, David Gordon, Vera Hirsh, Kaoru Kubota, Sergey Orlov, Gary Thomas, Tilman Steinmetz, Jin-Hyoung Kang, Dianne K Tomita, Alexander N Fleishman, Joseph K Park, Cisio De Oliveira Brandao

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

  Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, KEYNOTE, Investigators

• Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

  Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpe?o J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, ?zg?ro?lu M, PACIFIC Investigators.

• Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial.

  Horinouchi H, Kubota K, Miyanaga A, Nakamichi S, Seike M, Gemma A, Yamane Y, Kurimoto F, Sakai H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Tamura T, Ohe Y

• Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

  Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpe?o J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, ?zg?ro?lu M, PACIFIC Investigators.

• Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K

• A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.

  Scagliotti G, Nishio M, Satouchi M, Valmadre G, Niho S, Galetta D, Cortinovis D, Benedetti F, Yoshihara E, Makris L, Inoue A, Kubota K

• Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.

  Kubota K, Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T

• Rapport between Cancer Patients and Their Physicians is Critical for Patient Satisfaction with Treatment Decisions.

  Umihara J, Nishikitani M, Kubota K

• A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.

  K.Kubota,H.Sakai,N.Katakami,M.Nishio,A.Inoue,H.Okamoto,H.Isobe,H.Kunitoh,Y.Takiguchi,K.Kobayashi,Y.Nakamura,H.Ohmatsu,S.Sugawara,K.Minato,M.Fukuda,A.Yokoyama,M.Takeuchi,H.Michimae,A.Gemma&S.Kudoh,fortheTokyoCooperativeOncologyGroup

• We're in this together: Patients', caregivers' and health care providers' illness perceptions about non-small-cell lung cancer (NSCLC).

  Kaptein AA, Kobayashi K, Matsuda A, Kubota K, Nagai S, Momiyama M, Sugisaki M, Bos BC, Warning TD, Dik H, Klink Rv, Inoue K, Ramai R, Taube C, Kroep JR, Fischer MJ

• Effect of communication skills training program for oncologists based on patient preferences for communication when receiving bad news: a randomized controlled trial.

  Fujimori M, Shirai Y, Asai M, Kubota K, Katsumata N, Uchitomi Y

• Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.

  Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T, Japan Clinical Oncology Group.

• Short hydration in chemotherapy containing cisplatin (?75 mg/m2) for patients with lung cancer: a prospective study.

  Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T

• Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.

  Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihira S, Noro R, Minegishi Y, Seike M, Yoshimura A, Gemma A

• International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

  Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR

• A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.

  Kubota K, Sakai H, Yamamoto N, Kunitoh H, Nakagawa K, Takeda K, Ichinose Y, Saijo N, Ariyoshi Y, Fukuoka M

• Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.

  Grossi F, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, Aita M, Douillard JY

• Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.

  Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, Saijo N, Fukuoka M

• Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

  Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M, Mack PC

• Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.

  Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K, Japan Multi-National Trial Organisation.

• Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.

  Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoyama A, Noda K, Fukuoka M, Saijo N

• Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.

  Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, Monnier A, Kudoh S, Rubio JE, Cucherat M

• First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.

  Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Saijo N, Nishiwaki Y

• Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.

  Kubota K, Nishiwaki Y, Sugiura T, Noda K, Mori K, Kawahara M, Negoro S, Watanabe K, Imamura F, Tamura T, Saijo N

• Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.

  Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H, Japanese Taxotere Lung Cancer Study Group.

• Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902.

  Kubota K1, Tamura T, Fukuoka M, Furuse K, Ikegami H, Ariyoshi Y, Kurita Y, Saijo N

• Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer.

  Kubota K1, Nishiwaki Y, Kakinuma R, Hojo F, Matsumoto T, Ohmatsu H, Sekine I, Yokozaki M, Goto K, Ebi N, Kodama T.

• Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.

  Furuse K1, Kubota K, Kawahara M, Kodama N, Ogawara M, Akira M, Nakajima S, Takada M, Kusunoki Y, Negoro S, et al.

• Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer.

  Kubota K1, Furuse K, Kawahara M, Kodama N, Yamamoto M, Ogawara M, Negoro S, Masuda N, Takada M, Matsui K, et al.

その他

• 【受賞】2005年　田宮記念賞

• 【受賞】2013年　日本サイコオンコロジー学会 教育功労賞

• 【受賞】2013年　JCOG 下山正徳賞

• 【受賞】2018年　Annals of Oncology 賞

• 【受賞】2019年　東京都医師会 医学研究賞奨励賞